WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$54.65 (−45.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
GeneDx Holdings Corp. grew revenue 25.4% to $454.43M over the twelve months to Jun 30, 2026. Operating income fell 1800.3% to -$92.41M, moving the operating margin from 1.5% to -20.3%. Free cash flow was -$75.80M, down 9232.3% from a year earlier.
Revenue
$454.43M
+25.4% vs. a year earlier
Operating income
-$92.41M
-1800.3% vs. a year earlier
Free cash flow
-$75.80M
-9232.3% vs. a year earlier
EPS, diluted
-$3.64
-18300.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.97B
- P/E ratio
- –
- Price to sales
- 4.33
- Price to book
- 8.06
- Dividend yield
- –
- Free cash flow yield
- -3.85%
Fundamentals
- Revenue
- $454.43M
- Net income
- -$106.36M
- EPS, diluted
- -$3.64
- Free cash flow
- -$75.80M
- Book value per share
- $8.22
- Diluted shares
- 30M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$454.43M+25.4% YoY
Gross profit
$315.24M+29.5% YoY
Operating income
-$92.41M-1800.3% YoY
Net income
-$106.36M-7664.5% YoY
EPS, diluted
-$3.64-18300.0% YoY
Free cash flow
-$75.80M-9232.3% YoY
Reported periodTrailing twelve months